Sab
Founded 2014 · 88 employees on LinkedIn · 1 known investors
SAB BIO develops disease-modifying therapeutics for Type 1 Diabetes that target the underlying autoimmune causes rather than managing symptoms. The company's lead candidate, SAB-142, aims to preserve insulin-producing beta cell function in patients with Type 1 Diabetes.
Investors · 1
Frequently asked questions
- What does Sab do?
- SAB BIO develops disease-modifying therapeutics for Type 1 Diabetes that target the underlying autoimmune causes rather than managing symptoms. The company's lead candidate, SAB-142, aims to preserve insulin-producing beta cell function in patients with Type 1 Diabetes.
- Who are Sab's investors?
- Sab's investors include JDRF T1D Fund.